PE20210469A1 - USEFUL SUBSTITUTE NAPHTHYRIDINONE COMPOUNDS AS T-CELL ACTIVATORS - Google Patents
USEFUL SUBSTITUTE NAPHTHYRIDINONE COMPOUNDS AS T-CELL ACTIVATORSInfo
- Publication number
- PE20210469A1 PE20210469A1 PE2020002111A PE2020002111A PE20210469A1 PE 20210469 A1 PE20210469 A1 PE 20210469A1 PE 2020002111 A PE2020002111 A PE 2020002111A PE 2020002111 A PE2020002111 A PE 2020002111A PE 20210469 A1 PE20210469 A1 PE 20210469A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- compounds
- cell activators
- substituted
- useful substitute
- Prior art date
Links
- 229940126530 T cell activator Drugs 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen los compuestos de la Formula (I) donde R1 es H, F, Cl, Br, -CN entre otros; R2 es H, alquilo C1-C3 sustituido con cero a 4 R2a, o cicloalquilo C3-C4 sustituido con 4R2a ;cada R2a es independientemente F, Cl, -CN, -OH, -O (C1-C2 alquilo), C3-C4 cicloalquilo, C3-C4 alquenilo, o C3 - C4 alquinilo; R3 es H, F, Cl, Br, -CN, R4 es -CH2R4a, -CH2CH2R4a, -CHR4aR4b; R4a y R4b son independientemente alquilo C1-C6 sustituido con 4 sustituyentes seleccionados independientemente de F, Cl, -CN, -OH, -OCH3, -SCH3, entre otros; cada R5 es independientemente -CN, alquilo C1-C6 sustituido con 4 Rg, alquenilo C2-C4 sustituido con 4 Rg; cada Rg es independientemente F, Cl, -CN, -OH, alcoxi C1-C3, fluoroalcoxi C1-C3; m es 1, 2 o 3. Estos compuestos son utiles en el tratamiento de infecciones virales y trastornos proliferativos, como el cancer.Compounds of Formula (I) are described where R1 is H, F, Cl, Br, -CN among others; R2 is H, C1-C3 alkyl substituted with zero to 4 R2a, or C3-C4 cycloalkyl substituted with 4R2a; each R2a is independently F, Cl, -CN, -OH, -O (C1-C2 alkyl), C3-C4 cycloalkyl, C3-C4 alkenyl, or C3-C4 alkynyl; R3 is H, F, Cl, Br, -CN, R4 is -CH2R4a, -CH2CH2R4a, -CHR4aR4b; R4a and R4b are independently C1-C6 alkyl substituted with 4 substituents independently selected from F, Cl, -CN, -OH, -OCH3, -SCH3, among others; each R5 is independently -CN, C1-C6 alkyl substituted with 4 Rg, C2-C4 alkenyl substituted with 4 Rg; each Rg is independently F, Cl, -CN, -OH, C1-C3 alkoxy, C1-C3 fluoroalkoxy; m is 1, 2, or 3. These compounds are useful in treating viral infections and proliferative disorders, such as cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690439P | 2018-06-27 | 2018-06-27 | |
| US201962840459P | 2019-04-30 | 2019-04-30 | |
| PCT/US2019/039135 WO2020006018A1 (en) | 2018-06-27 | 2019-06-26 | Substituted naphthyridinone compounds useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210469A1 true PE20210469A1 (en) | 2021-03-08 |
Family
ID=67439335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002111A PE20210469A1 (en) | 2018-06-27 | 2019-06-26 | USEFUL SUBSTITUTE NAPHTHYRIDINONE COMPOUNDS AS T-CELL ACTIVATORS |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10669272B2 (en) |
| EP (1) | EP3814348B9 (en) |
| JP (1) | JP7432532B2 (en) |
| KR (1) | KR102767739B1 (en) |
| CN (1) | CN112654621B (en) |
| AU (1) | AU2019291794B2 (en) |
| BR (1) | BR112020026681A2 (en) |
| CA (1) | CA3104654A1 (en) |
| CL (1) | CL2020003260A1 (en) |
| DK (1) | DK3814348T3 (en) |
| ES (1) | ES2960754T3 (en) |
| FI (1) | FI3814348T3 (en) |
| HR (1) | HRP20231253T1 (en) |
| HU (1) | HUE064531T2 (en) |
| IL (1) | IL279728B2 (en) |
| LT (1) | LT3814348T (en) |
| MX (1) | MX2020013817A (en) |
| PE (1) | PE20210469A1 (en) |
| PL (1) | PL3814348T3 (en) |
| PT (1) | PT3814348T (en) |
| RS (1) | RS64641B1 (en) |
| SG (1) | SG11202012972YA (en) |
| SI (1) | SI3814348T1 (en) |
| SM (1) | SMT202300466T1 (en) |
| TW (1) | TW202019924A (en) |
| WO (1) | WO2020006018A1 (en) |
| ZA (1) | ZA202100555B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111471059B (en) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | PDE9 inhibitors and uses thereof |
| KR20220012244A (en) | 2019-04-29 | 2022-02-03 | 솔렌트 테라퓨틱스, 엘엘씨 | 3-Amino-4H-benzo[E][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 |
| AR119821A1 (en) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS |
| CN115210225A (en) | 2019-11-28 | 2022-10-18 | 拜耳公司 | Substituted aminoquinolones as immuno-activated DGKALPHA inhibitors |
| CA3163107A1 (en) | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| GEP20247646B (en) | 2019-11-28 | 2024-07-25 | Bayer Ag | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021127554A1 (en) * | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| CA3162985A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted quinazolinyl compounds useful as t cell activators |
| WO2021133752A1 (en) * | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted heteroaryl compounds useful as t cell activators |
| AR120823A1 (en) * | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS |
| MX2022007130A (en) * | 2019-12-23 | 2022-07-11 | Bristol Myers Squibb Co | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS. |
| ES2998500T3 (en) * | 2019-12-23 | 2025-02-20 | Bristol Myers Squibb Co | Substituted quinolinonyl piperazine compounds useful as t cell activators |
| MX2022007930A (en) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds. |
| AR120896A1 (en) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | PYRIDAZINIL-THIAZOLCARBOXAMIDE COMPOUNDS AS DGKz INHIBITORS |
| CN120093741A (en) * | 2020-04-24 | 2025-06-06 | 拜耳公司 | Substituted aminothiazoles as DGKZETA inhibitors for immune activation |
| WO2021258010A1 (en) * | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| KR102682398B1 (en) * | 2020-11-26 | 2024-07-05 | 주식회사 엘지화학 | Heterocyclic compound as diacylglycerol kinases inhibitor and use thereof |
| CR20230415A (en) * | 2020-11-30 | 2023-09-08 | Kotobuki Pharmaceutical Co Ltd | Heteroaryl carboxamide compound |
| AU2021400725A1 (en) | 2020-12-16 | 2023-08-03 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (en) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | DIACYL GLYCEROL KINASE MODULATING COMPOUNDS. |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| EP4472963A1 (en) * | 2022-02-01 | 2024-12-11 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| TW202342477A (en) | 2022-03-01 | 2023-11-01 | 香港商英矽智能科技知識產權有限公司 | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| AR128668A1 (en) * | 2022-03-01 | 2024-06-05 | Insilico Medicine Ip Ltd | DIACYL GLYCEROL KINASE (DGK) INHIBITORS AND USES THEREOF |
| WO2023178035A1 (en) | 2022-03-14 | 2023-09-21 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| JP2025531850A (en) | 2022-09-08 | 2025-09-25 | ジュノー セラピューティクス インコーポレイテッド | Combination of T cell therapy and continuous or intermittent DGK inhibitor dosing |
| CN120813352A (en) | 2023-02-06 | 2025-10-17 | 拜耳公司 | Combinations of DGK (diacylglycerol kinase) inhibitors |
| CN116375654B (en) * | 2023-03-22 | 2024-12-31 | 湖北三峡实验室 | Method for preparing 2, 5-diketopiperazine from diglycolamine |
| CN119143715B (en) * | 2024-11-12 | 2025-03-14 | 天津匠新致成科技有限公司 | Diaryl methylpiperazine compound and preparation method, pharmaceutical composition and application thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| JP2005537247A (en) | 2002-06-27 | 2005-12-08 | シエーリング アクチエンゲゼルシャフト | Substituted quinoline CCR5 receptor antagonist |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| WO2004087880A2 (en) | 2003-03-26 | 2004-10-14 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| WO2005009967A2 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| MXJL06000006A (en) * | 2003-08-22 | 2006-05-04 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases. |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CA2602777C (en) | 2005-03-25 | 2018-12-11 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| BR122020016659B8 (en) | 2005-05-10 | 2021-07-27 | Incyte Holdings Corp | indoleamine 2,3-dioxygenase modulators and methods of modulating inhibition and immunosuppression activity |
| KR101888321B1 (en) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
| ES2540561T3 (en) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hydroxyamidinoheterocycles as indolamine 2,3-dioxygenase modulators |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (en) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | Cinnamoyl compounds and uses thereof |
| JP2007308441A (en) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | Heterocyclic compounds and uses thereof |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| WO2009156652A1 (en) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Cellular structure containing aluminium titanate |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| SG178991A1 (en) | 2009-09-03 | 2012-04-27 | Schering Corp | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| SI2949670T1 (en) | 2009-12-10 | 2019-05-31 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| JP5989547B2 (en) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Antibody to human CSF-1R and use thereof |
| MX2012010014A (en) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Antibodies against human csf-1r and uses thereof. |
| ES2706412T3 (en) | 2010-05-04 | 2019-03-28 | Five Prime Therapeutics Inc | Antibodies that bind to CSF1R |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| CA2810359C (en) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| WO2012142498A2 (en) | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
| ES2669310T3 (en) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Antibodies and other molecules that bind with B7-H1 and PD-1 |
| LT2785375T (en) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODIES AND THEIR USE |
| MX356337B (en) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Antibodies against human csf-1r and uses thereof. |
| CN104093740B (en) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | Use the composition and method of CSF1R inhibitor |
| US9006257B2 (en) | 2012-02-09 | 2015-04-14 | Glenmark Pharmaceuticals S.A. | Bicyclic compounds as mPGES-1 inhibitors |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| KR20150018533A (en) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csfir) |
| UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| KR20150047593A (en) | 2012-08-31 | 2015-05-04 | 파이브 프라임 테라퓨틱스, 인크. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| EA201792214A1 (en) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | COMPOUNDS OF SUBSTITUTE QUINAZOLINE |
| NZ742476A (en) | 2015-12-17 | 2022-09-30 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| CN107216325B (en) | 2016-03-22 | 2019-06-25 | 上海医药工业研究院 | Naphthyridone compound, its preparation method and application |
| WO2017177037A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| SI3558955T1 (en) | 2016-12-22 | 2021-12-31 | Amgen Inc., | Benzisothiazole, isothiazole (3,4-b) pyridine, quinazoline, phthalazine, pyrido (2,3-d) pyridazine and pyrido (2,3-D) pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung cancer, pancreatic cancer or colorectal cancer |
| WO2018134885A1 (en) | 2017-01-17 | 2018-07-26 | 初実 田中 | Assist encouragement system and assist encouragement method |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| WO2019005883A1 (en) | 2017-06-26 | 2019-01-03 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| EP4509512A3 (en) | 2018-03-07 | 2025-04-09 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| JP7312745B2 (en) | 2018-06-07 | 2023-07-21 | 第一三共株式会社 | Azetidine derivatives and their prodrugs |
| TWI833770B (en) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | Compounds and methods for reducing lrrk2 expression |
| TWI841573B (en) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | Amino acid compounds with unbranched linkers and methods of use |
| MX2020013895A (en) | 2018-06-27 | 2021-07-21 | Biogen Ma Inc | Ask1 inhibiting agents. |
| WO2020004594A1 (en) | 2018-06-27 | 2020-01-02 | 株式会社リボルナバイオサイエンス | Prophylactic or therapeutic agent for spinal muscular atrophy |
| MX2020013805A (en) | 2018-06-27 | 2021-03-09 | Oscotec Inc | Pyridopyrimidinone derivatives for use as axl inhibitors. |
| BR112020026580A2 (en) | 2018-06-27 | 2021-03-23 | Proteostasis Therapeutics, Inc. (Fem) | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATING A PATIENT |
-
2019
- 2019-06-26 SG SG11202012972YA patent/SG11202012972YA/en unknown
- 2019-06-26 ES ES19744923T patent/ES2960754T3/en active Active
- 2019-06-26 SI SI201930609T patent/SI3814348T1/en unknown
- 2019-06-26 HU HUE19744923A patent/HUE064531T2/en unknown
- 2019-06-26 HR HRP20231253TT patent/HRP20231253T1/en unknown
- 2019-06-26 PL PL19744923.4T patent/PL3814348T3/en unknown
- 2019-06-26 PT PT197449234T patent/PT3814348T/en unknown
- 2019-06-26 SM SM20230466T patent/SMT202300466T1/en unknown
- 2019-06-26 PE PE2020002111A patent/PE20210469A1/en unknown
- 2019-06-26 LT LTEPPCT/US2019/039135T patent/LT3814348T/en unknown
- 2019-06-26 DK DK19744923.4T patent/DK3814348T3/en active
- 2019-06-26 WO PCT/US2019/039135 patent/WO2020006018A1/en not_active Ceased
- 2019-06-26 MX MX2020013817A patent/MX2020013817A/en unknown
- 2019-06-26 JP JP2020572691A patent/JP7432532B2/en active Active
- 2019-06-26 AU AU2019291794A patent/AU2019291794B2/en active Active
- 2019-06-26 RS RS20230895A patent/RS64641B1/en unknown
- 2019-06-26 EP EP19744923.4A patent/EP3814348B9/en active Active
- 2019-06-26 CA CA3104654A patent/CA3104654A1/en active Pending
- 2019-06-26 CN CN201980055715.8A patent/CN112654621B/en active Active
- 2019-06-26 US US16/452,679 patent/US10669272B2/en active Active
- 2019-06-26 FI FIEP19744923.4T patent/FI3814348T3/en active
- 2019-06-26 KR KR1020217002231A patent/KR102767739B1/en active Active
- 2019-06-26 BR BR112020026681-7A patent/BR112020026681A2/en unknown
- 2019-06-27 TW TW108122537A patent/TW202019924A/en unknown
-
2020
- 2020-04-08 US US16/843,024 patent/US10954238B1/en active Active
- 2020-12-16 CL CL2020003260A patent/CL2020003260A1/en unknown
- 2020-12-23 IL IL279728A patent/IL279728B2/en unknown
-
2021
- 2021-01-26 ZA ZA2021/00555A patent/ZA202100555B/en unknown
- 2021-02-01 US US17/164,009 patent/US11713316B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210469A1 (en) | USEFUL SUBSTITUTE NAPHTHYRIDINONE COMPOUNDS AS T-CELL ACTIVATORS | |
| AR119821A1 (en) | SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS | |
| PE20211779A1 (en) | PYRAZOLE [3,4-b] PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | |
| ES2721268T3 (en) | Pyrazolo [1,5-a] pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | |
| AR120823A1 (en) | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS | |
| AR109315A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF REPLACED POLICYCLIC PIRIDONE AND PROPHARM OF THE SAME | |
| AR093404A1 (en) | MACROCICLICAL COMPOUNDS THAT MODULATE THE ACTIVITY OF APOPTOSIS INHIBITORS | |
| ECSP22046699A (en) | KRAS G12C INHIBITORS | |
| PE20211911A1 (en) | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | |
| PE20190336A1 (en) | NEW AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| PE20151981A1 (en) | ZESTE APPROVAL INHIBITOR PONTENCER | |
| PE20191811A1 (en) | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | |
| PE20181449A1 (en) | USEFUL COMPOUNDS AS KINASE INHIBITORS | |
| AR094452A1 (en) | HETEROCYCLIC COMPOUNDS REPLACED WITH AMIDA USEFUL AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR INFa | |
| PE20191613A1 (en) | PYRAZOLE [1,5-A] PYRIDINE COMPOUNDS SUBSTITUTED AS INHIBITORS OF RET KINASE | |
| PE20201448A1 (en) | METHYL MODIFYING ENZYME MODULATORS, COMPOSITIONS AND USES OF THEM | |
| PE20190710A1 (en) | INDOL CARBOXAMIDE COMPOUNDS USED AS KINASE INHIBITORS | |
| PE20180117A1 (en) | INDOLAMINE-2,3-DIOXYGENASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| AR066448A1 (en) | MACROCICLICAL INHIBITORS OF THE REPAIR OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, METHODS OF OBTAINING THE COMPOUND AND INTERMEDIARY COMPOUNDS | |
| PE20240886A1 (en) | SPIROCYCLIC COMPOUNDS | |
| PE20190979A1 (en) | HETEROARILCARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | |
| PE20191814A1 (en) | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | |
| MX2021008252A (en) | PYRIMIDINE COMPOUND OR SALT THEREOF. | |
| AR119074A1 (en) | 1-PHENYL-5-AZINILPYRAL-3-OXYALKYL ACIDS AND THEIR USE TO COMBAT UNWANTED PLANT GROWTH | |
| AR059886A1 (en) | DERIVATIVES OF AMIDAS AS INHIBITORS OF RENINA |